Software algorithm offers rapid diagnosis, acute care for those with status epilepticus

A Bay Area neurotechnology firm has announced the commercial release of a novel artificial intelligence-based software algorithm that continuously monitors brain activity of those with electrographic status epilepticus.

According to a release from Ceribell Inc, ClarityPro is the first acute care device to be FDA indicated for standalone diagnosis, as well as the first critical care monitoring device to secure FDA breakthrough designation. The algorithm can diagnose and alert clinicians to the condition, allowing real-time data to be acquired to quickly identify and treat seizures.

In a hospital setting, ClarityPro allows health care professionals involved with acute care to expand brain monitoring capabilities, while aiding in the reduction of unnecessary medication, intubations and patient transfers and shortening intensive care unit stays, the company said in the release.

“Every minute counts when it comes to treating status epilepticus. Ceribell is dedicated to expanding access to neurodiagnostics, which is essential to improving patient care and outcomes,” Jane Chao, PhD, co-founder and CEO of Ceribell, said in the release. “ClarityPro harnesses the power of AI to bring acute seizure management to a new level, helping clinicians make precise treatment decisions while also helping hospitals extend care to more patients.”